A Randomized Phase 3 Study of MRTX849 in Combination With Cetuximab Versus Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation With Disease Progression On or After Standard First-Line Therapy
A Randomized Phase 3 Study of MRTX849 in Combination With Cetuximab Versus Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation With Disease Progression On or After Standard First-Line Therapy
Study CA239-0006 is an open-label, randomized Phase 3 clinical trial comparing the efficacy of MRTX849 administered in combination with cetuximab versus chemotherapy in the second-line treatment setting in patients with CRC with KRAS G12C mutation.
Inclusion Criteria:
Exclusion Criteria:
Brownstown, Michigan 48183, United States
CABA, 1061, Argentina
Porto Alegre, 91350-200, Argentina
Shanghai Shi, Shanghai Municipality 200025, China
Shanghaishi, Shanghai Municipality 200032, China
Hongkou Qu, 200080, China
Colonia Centro Orizaba, Veracruz 94300, Mexico
Hwasun-gun, 58128, South Korea
LHospitalet de Llobregat, 08908, Spain
Khlong Toey, 10110, Thailand
Dorset, BH7 7DW, United Kingdom